Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage, multi-modality oncology company developing novel small-molecule therapeutics for highly aggressive cancers by targeting tumor-specific vulnerabilities such as aneuploidy and immunogenicity. Co-founded by Tak Wah Mak, PhD and Mark R. Bray, PhD, the company keeps drug discovery and clinical development under one roof and works out of Toronto (with a research footprint at the University Health Network), New York and Hong Kong. Its internally developed pipeline includes CFI-400945, an oral PLK4 inhibitor in Phase 1/2 studies across triple-negative breast cancer, prostate cancer and acute myeloid leukemia (FDA Fast Track designation); CFI-402257, a TTK inhibitor in Phase 1b/2; and CFI-402411, a first-in-class HPK1 inhibitor. Treadwell is a therapeutics developer, not a software vendor - it publishes no developer program, no public API, and no machine-readable API contract. Profiled by API Evangelist from its own public corporate site.
Treadwell Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Life Sciences.
Treadwell Therapeutics’ developer surface includes engineering blog and 7 more developer resources.
Kin Score
Pricing Plans 1
Published pricing tiers and plan structures.
Rate Limits 1
Documented rate limits and quota policies.
Treadwell Therapeutics Rate Limits
RATE LIMITSSecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 3
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.